Ramucirumab

Cyramza

欣銳擇注射劑

100mg/10ml/vial

04. ANTINEOPLASTIC AGENTS; ;

04.05. MONOCLONAL ANTIBODIES;;

Monoclonal antibodies

晚期或轉移性胃腺癌(或胃食道接合處腺癌)

Contraindication

Unknown

IVF(over 60min)
Colorectal cancer, Gastric cancer, Hepatocellular carcinoma
8 mg/kg every 2 weeks as a single agent or in combination with paclitaxel
Non–small cell lung cancer, metastatic
First-line treatment in tumors with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations:
10 mg/kg once every 2 weeks (in combination with erlotinib) until disease progression or unacceptable toxicity
Disease progression on or after platinum-based therapy:
10 mg/kg on day 1 every 21 days in combination with docetaxel; continue ramucirumab until disease progression or unacceptable toxicity

Hypertension, Proteinuria, Infusion related reaction, Diarrhea, Bone marrow suppression

1.治療期間應監測蛋白尿，當蛋白尿>2g/24hr，請暫停使用Cyramza。一旦尿蛋白恢復<2g/24hr，以調整後的劑量重新開始。當蛋白尿>3g/24hr或出現腎病症候群應永久停用Cyramza。
2.動脈血栓栓塞事件，胃腸穿孔、地3或第4級出血應永久停用Cyramza。
3.開始接受Cyramza治療前，請先控制已存在的高血壓。治療期間請依指示每兩週或更頻繁的監測血壓。出現高血壓請暫停使用Cyramza，直到高血壓被藥物控制為止。
4.於排定的手術前至完全癒合為止請暫停使用Cyramza。
5.治療期間應監測甲狀腺功能。
6.治療期間至最後一劑治療Cyramza後，至少3個月內應採用適當的避孕措施以避免懷孕

建立者

104784

建立時間

2017-03-29 14:20:45

維護者

103617

維護時間

2024-01-24 09:36:00